No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening - PubMed (original) (raw)

No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening

Beverly E Hird et al. Arch Dis Child. 2014 Feb.

Abstract

Objective: Congenital adrenal hyperplasia (CAH) is not currently included in the UK newborn screening programme. We investigated the hypothesis that, owing to non-specificity of symptoms, a proportion of males affected by salt-wasting (SW) CAH have died in infancy without being diagnosed.

Design: Stored newborn screening blood spot samples were analysed for 17α-hydroxyprogesterone (17-OHP) in the following groups: Infants born in the North West of England, 1994 to 2006, who had died by 6 months age; (n=1198), a neonatal reference group (full-term n=100; preterm n=100) and a CAH positive control group. A newborn blood spot sample collected before diagnosis was available in 29/61 CAH patients recruited. SW CAH was present in 18/29 patients (16 males and 2 females). Samples from the deceased group with elevated 17-OHP were analysed for 8 common mutations in the 21-hydroxylase gene (CYP21A2).

Setting: North West of England.

Results: Grouped by gestational age, mean (maximum) blood spot 17-OHP in nmol/L was as follows. Deceased full-term n=279, 6 (107); deceased premature n=365, 28 (251); deceased unknown gestational age n=553, 13 (>394). In the SW positive control group, the lowest level of 17-OHP was 179 nmol/L and 14 had levels greater than the highest standard (>268 to >420 nmol/L). All samples from the deceased group with 17-OHP results >179 nmol/L (n=6) and a further 13 samples underwent mutation analysis. No mutations were identified.

Conclusions: Our findings do not support the hypothesis that, in our unscreened population, males affected by SW CAH are dying prior to diagnosis.

Keywords: 21-hydroxylase deficiency; Congenital adrenal hyperplasia; infant mortality; neonatal screening; newborn screening.

PubMed Disclaimer

Cited by

The use of liquid chromatography-tandem mass spectrometry in newborn screening for congenital adrenal hyperplasia: improvements and future perspectives.
de Hora M, Heather N, Webster D, Albert B, Hofman P. de Hora M, et al. Front Endocrinol (Lausanne). 2023 Oct 2;14:1226284. doi: 10.3389/fendo.2023.1226284. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37850096 Free PMC article. Review.
The Cost-Effectiveness of Congenital Adrenal Hyperplasia Newborn Screening in Brazil: A Comparison Between Screened and Unscreened Cohorts.
de Miranda MC, Haddad LBP, Trindade E, Cassenote A, Hayashi GY, Damiani D, Costa FC, Madureira G, de Mendonca BB, Bachega TASS. de Miranda MC, et al. Front Pediatr. 2021 May 24;9:659492. doi: 10.3389/fped.2021.659492. eCollection 2021. Front Pediatr. 2021. PMID: 34109139 Free PMC article.
[Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia: Benefits and costs of a successful public health program].
Van Vliet G, Grosse SD. Van Vliet G, et al. Med Sci (Paris). 2021 May;37(5):528-534. doi: 10.1051/medsci/2021053. Epub 2021 May 18. Med Sci (Paris). 2021. PMID: 34003099 Free PMC article.
Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.
Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenström A, Reisch N, Sandberg DE, Stikkelbroeck NMML, Touraine P, Utari A, Wudy SA, White PC. Claahsen-van der Grinten HL, et al. Endocr Rev. 2022 Jan 12;43(1):91-159. doi: 10.1210/endrev/bnab016. Endocr Rev. 2022. PMID: 33961029 Free PMC article. Review.
Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia.
Grosse SD, Van Vliet G. Grosse SD, et al. Int J Neonatal Screen. 2020 Oct 25;6(4):82. doi: 10.3390/ijns6040082. Int J Neonatal Screen. 2020. PMID: 33239603 Free PMC article. Review.

No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening - PubMed (original) (raw)